An2 Therapeutics Inc (ANTX) Stock Price, Quote & News

Latest News on ANTX

Mar 25, 2025, 4:00 PM EDT - 8 days ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights

Mar 3, 2025, 4:00 PM EST - 4 weeks ago

AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

$AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease$

Feb 24, 2025, 7:00 AM EST - 5 weeks ago

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

Feb 20, 2025, 7:00 AM EST - 5 weeks ago

AN2 Therapeutics to Participate at Upcoming Investor Conferences

Jan 29, 2025, 4:00 PM EST - 2 months ago

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nov 13, 2024, 4:00 PM EST - 5 months ago

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

Oct 17, 2024, 7:00 AM EDT - 5 months ago

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

Aug 28, 2024, 4:00 PM EDT - 7 months ago

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 7:00 AM EDT - 8 months ago

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

Aug 13, 2024, 4:01 PM EDT - 8 months ago

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

$AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease$

Aug 8, 2024, 4:30 PM EDT - 8 months ago

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

May 14, 2024, 4:01 PM EDT - 11 months ago

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Mar 28, 2024, 4:10 PM EDT - 1 year ago

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Feb 12, 2024, 6:56 AM EST - 1 year ago

AN2 Therapeutics to pause lung disease study enrollment

$AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease$

Feb 12, 2024, 6:45 AM EST - 1 year ago

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease

Jan 30, 2024, 4:10 PM EST - 1 year ago

AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference

Nov 9, 2023, 4:05 PM EST - 1 year ago

AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights

Nov 6, 2023, 7:00 AM EST - 1 year ago

AN2 Therapeutics to Present at Upcoming Investor Conferences

Oct 18, 2023, 7:00 AM EDT - 1 year ago

AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease

Oct 11, 2023, 12:01 AM EDT - 1 year ago

AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023

Sep 26, 2023, 7:00 AM EDT - 1 year ago

AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria

$AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease$